ADORA2A and autoimmune disease: Li and collaborators have already showed that administration of the A2AR agonist, CGS21680C, 29 days post EAMG induction (therapeutic treatment) ameliorated disease severity and decreased the number of Th1 and Th2 cells while increasing the number of Treg cells [8], thus suggesting that targeting A2AR may have putative therapeutic applications in T cell-based autoimmune diseases.